Altimmune says weight loss drug minimized muscle loss in trial results that may set it apart
- The results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that they shrink critical muscle mass.
- 03/27/2024
|
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
- GAITHERSBURG, Md., March 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.
- 03/20/2024
|
Altimmune stock price forecast: brace for more ALT volatility
- Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company's stock surged by more than 580% from its lowest level in 2023.
- 02/28/2024
|
Why Is Altimmune (ALT) Stock Up 14% Today?
- Altimmune (NASDAQ: ALT ) stock is rising higher on Monday but it's not actually due to any news from the clinical-stage biopharmaceutical company. Instead, a clinical trial update from rival Zealand Pharma is behind the increase in ALT stock today.
- 02/26/2024
|
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
- With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.
- 02/22/2024
|
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
- Kerrisdale Capital is at it again, this time revealing a short position in struggling biotech firm Altimmune (NASDAQ: ALT ). The acclaimed short seller has just released a damning short report on the company, saying that its only viable product, a weight-loss drug, has little chance of commercial success and will “bomb” in upcoming Phase 3 trials.
- 02/13/2024
|
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
- Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
- 01/25/2024
|
MoneyShow's Best Investment Ideas For 2024: Part 1
- MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income. Part 1 of this series includes Academy Sports and Outdoors, Agnico Eagle Mines, Alphabet, Altimmune, and Arista Networks, among others.
- 01/25/2024
|
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
- Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
- 01/25/2024
|
2 biotechs with promising weight-loss drugs coming
- Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S NYSE: NVO owned Ozempic and Wegovy and Eli Lilly and Co. NYSE: LLY owned Mounjaro and Zepbound continue to see demand outstrip supply.
- 01/16/2024
|
Up for 8 straight weeks, is Altimmune (ALT) stock a good buy?
- The Altimmune (NASDAQ: ALT) stock price has been in a strong uptrend in the past few months. It bottomed at $2.07 in October, and the shares have surged by over 475% to its highest level since February.
- 01/10/2024
|
The 3 Best Biotech Stocks to Buy in January 2024
- Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks. Look at obesity drug stocks, like Eli Lilly (NYSE: LLY ) for example.
- 01/09/2024
|
Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?
- The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.
- 12/20/2023
|
Can Altimmune's weight-loss drug be a game-changer?
- The runaway success of weight-loss drugs like Novo Nordisk A/S NYSE: NVO Ozempic and Eli Lilly and Co. NYSE: LLY Mounjaro has kicked off a gold rush for new weight-loss drugs in the medical sector. One of the major complaints about glucagon-like peptide-1 (GLP-1) drugs is the nausea and vomiting that comes with the usage of these drugs.
- 12/14/2023
|
Is Altimmune (ALT) stock a good buy after the 306% jump?
- Altimmune (NASDAQ: ALT) stock proce has staged a strong recovery in the past few days, making it one of the most popular companies among day traders. The shares jumped to a high of $8.63 on Thursday, about 306% above the lowest point this year, giving it a market cap of over $353 million.
- 12/08/2023
|
Call Traders Targeting Rallying Weight-Loss Drug Developer
- Options traders are targeting Altimmune Inc (NASDAQ:ALT), as the stock shoots for its 11th-straight win.
- 12/07/2023
|
Altimmune shares pop as analysts see obesity-drug partnership potential
- Altimmune Inc. shares ALT, +1.02% gained 5% Thursday and have jumped more than 100% this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.
- 12/07/2023
|
Altimmune (ALT) Rises 83% on Successful Phase II Obesity Study
- Altimmune (ALT) reports positive top-line data from its 48-week phase II MOMENTUM study of obesity drug candidate, pemvidutide. The stock gains 83%.
- 12/04/2023
|
Why Is Altimmune (ALT) Stock Up 43% Today?
- Altimmune (NASDAQ: ALT ) stock is rising higher on Friday after the company posted positive results from a weight loss drug trial. Those results come from the biopharmaceutical company's Phase 2 obesity trial of pemvidutide.
- 12/01/2023
|
Here's why penny stocks like GGE, NEXI, ALT, HCDI are pumping
- Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.
- 12/01/2023
|
5 Hot Penny Stocks To Watch In The Stock Market Today
- Whether you're looking for the best penny stocks to buy, the most active stocks today, or just trying to plan out your next long-term investment, understanding things like stock market news and events is important.
- 10/25/2023
|
Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023
- GAITHERSBURG, Md., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide from its 24-week Phase 1b randomized, placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) will be presented in a late-breaking poster presentation at The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA (November 10-14, 2023). Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
- 10/25/2023
|
Altimmune to Participate at Two Upcoming Investor Conferences
- GAITHERSBURG, Md., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
- 10/17/2023
|
Altimmune: A Year Of Disappointment
- Altimmune's stock has disappointed shareholders over the past year, with disappointing trial results triggering a significant drop in equity in March of this year. The Company is developing treatments for NASH and hepatitis B. ALT stock sells for less than the net cash on the company's balance sheet.
- 10/11/2023
|
Penny Stocks To Buy? 3 Short Squeeze Stocks To Watch ASAP
- Penny stocks, typically defined as stocks trading under $5 per share, offer traders massive upside profit potential but also higher risk due to greater volatility. When penny stocks become heavily shorted, meaning a high percentage of the shares are held by investors betting the price will decline, it can set up a volatile “short squeeze.
- 09/15/2023
|
Altimmune (ALT) Rises 7% on Completing Dosing in Obesity Study
- Altimmune (ALT) completes the dosing of all patients in the mid-stage obesity study of pemvidutide. The company remains on track to announce top-line results in fourth-quarter 2023.
- 09/13/2023
|
Altimmune to Participate at Two Upcoming Investor Conferences
- GAITHERSBURG, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
- 08/30/2023
|
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
- GAITHERSBURG, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2023 financial results on Thursday, August 10, 2023 and will provide a business update.
- 08/03/2023
|
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
- Morgan Stanley on Friday lifted its forecast for annual sales of weight-loss drugs to $77 billion, as patient demand for the medicines has outstripped supply and been fueled by a social-media frenzy.
- 07/21/2023
|
Factbox: Weight-loss drugs: the next gold rush
- Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.
- 06/27/2023
|
Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023
- GAITHERSBURG, Md., June 16, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, has been invited to participate on a Metabolic panel at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th, 2023 at 11:00 A.M. ET.
- 06/16/2023
|
Altimmune to Participate at Two Upcoming Investor Conferences
- GAITHERSBURG, Md., May 31, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
- 05/31/2023
|
Altimmune to Participate at Two Upcoming Investor Conferences
- GAITHERSBURG, Md., May 08, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate and be available for 1x1 meetings at the following investor conferences:
- 05/08/2023
|
Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
- GAITHERSBURG, Md., May 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2023 financial results on Thursday, May 11, 2023 and will provide a business update.
- 05/04/2023
|
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
- The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022.
- 04/28/2023
|
Top Penny Stocks To Buy Now? 10 To Watch Under $5
- 10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 04/13/2023
|
7 Top Penny Stocks Under $5; Time To Buy Now?
- Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?
- 03/29/2023
|
4 Top Penny Stocks Under $5; Time To Buy Now?
- Penny stocks to buy for under $5. Are they worth it?
- 03/27/2023
|
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
- Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate.
- 03/22/2023
|
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
- Analysts had lofty expectations for Altimmune and the prospects for pemvidutide in treating obesity. However, pemvidutide's side effects in a phase 2 study were concerning.
- 03/22/2023
|
Why Is Altimmune (ALT) Stock Down 67% Today?
- Altimmune (NASDAQ: ALT ) stock is losing value on Tuesday after the company released results from a clinical trial. That trial has to do with the company's treatment for obesity.
- 03/21/2023
|
Altimmune's Peptide-Based Therapies Offer Substantial Opportunity
- Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to the discontinuation of certain projects, but the company has been actively advancing other programs that are expected to deliver noteworthy revenues soon.
- 02/23/2023
|
Altimmune: Potential Dual Action For Pemvidutide In Obesity, NASH
- Altimmune has exposure to promising growth areas of obesity and non-alcoholic liver disease treatment. Upcoming trial data and proof of concept work for its pemvidutide compound is key to see the stock rate higher.
- 02/21/2023
|
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
- GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 and will provide a business update.
- 02/21/2023
|
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
- Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
- 02/16/2023
|
7 Small-Cap Stocks with Big Growth Potential in 2023
- Some of the greatest opportunities can be found in these small-cap stocks to buy. For one, a good number of small-cap stocks are severely undervalued.
- 01/10/2023
|
Altimmune Stock Skyrockets on NAFLD Drug Trial Data
- Altimmune Inc (NASDAQ:ALT) and SINTX Technologies Inc (NASDAQ:SINT) are trending today.
- 12/21/2022
|
The 7 Hottest Biotech Stocks to Own in 2023 and Beyond
- Some of the hottest biotech stocks are safe and recession-proof. After all, we can't stop people from aging – at least, not yet.
- 12/18/2022
|
Altimmune Appears To Have A Winner, But Will The Market Believe?
- On September 14, shares plummeted 27% on topline results from a Phase 1 study of pemvidutide. Reductions in liver fat appear to be substantially better than that of the two leading drug candidates for nonalcoholic steatohepatitis.
- 12/02/2022
|
Altimmune to Participate at Two Upcoming Investor Conferences
- GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences:
- 11/22/2022
|
Altimmune, Inc. (ALT) Reports Q3 Loss, Misses Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.04% and 99.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2022
|
Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10
- GAITHERSBURG, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its third quarter 2022 financial results on Thursday, November 10, 2022 and will provide a business update.
- 11/03/2022
|
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®
- GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:
- 10/28/2022
|
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
- Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
- 09/15/2022
|
Altimmune: Overreaction On NASH Data Creates Buying Opportunity
- Altimmune stock was trading lower after the release of positive results, achieving both primary and secondary endpoints of phase 1b study with pemvidutide in NASH/obese patients provides a buying opportunity. It provided updated 24-week results from phase 1b study using pemvidutide in NASH/obese patients measuring weight loss expected Q4 of 2022.
- 09/15/2022
|
Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data
- Source: Shutterstock Altimune (NASDAQ: ALT ) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning. That clinical trial concerns the use of pemvidutide1 in treating patients with NAFLD.
- 09/14/2022
|
Altimmune's stock falls 44% after sharing data from trial for liver disease treatment
- Shares of Altimmune Inc. ALT, -0.39% tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic fatty liver disease that failed to impress investors. The Phase 1b study met both the primary and secondary endpoints of reduction in liver fat content and weight loss, respectively.
- 09/14/2022
|
Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2022 Results - Earnings Call Transcript
- Altimmune, Inc. (NASDAQ:ALT ) Q2 2022 Results Conference Call August 11, 2022 8:30 AM ET Company Participants Richard Eisenstadt - Chief Financial Officer Vipin Garg - President and Chief Executive Officer Scot Roberts - Chief Scientific Officer Scott Harris - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Yasmeen Rahimi - Piper Sandler Roger Song - Jefferies Mayank Mamtani - B. Riley Jon Welandon - JMP Securities Patrick Trucchio - H.C.
- 08/11/2022
|
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/11/2022
|
Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?
- Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.
- 07/18/2022
|
Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?
- Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.
- 06/30/2022
|
Altimmune: Several Catalysts In 2 Large Market Indications This Year
- Results from phase 1b NAFLD study using pemvidutide are to be released 2nd half of 2022;Q3 of 2022 will be 12-week data and Q4 of 2022 will be 24-week data. It is estimated that the global NASH market could be worth $20 billion by 2027.
- 06/28/2022
|
Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?
- Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
- 06/14/2022
|
Altimmune to Participate at Two Upcoming Investor Conferences
- GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in June 2022:
- 06/03/2022
|
Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, 2022
- GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Medicine and Nutritional Science Director, Washington University School of Medicine, will deliver an oral presentation at the 82nd American Diabetes Association (ADA) Scientific Sessions, to be held in New Orleans, LA on June 3-7, 2022. Dr. Klein will present the results of Altimmune's recently completed Phase 1, first-in-human clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH.
- 05/31/2022
|
Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022
- GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company's novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials.
- 05/20/2022
|
Altimmune to Present at Upcoming Investor Conferences
- GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate at the following investor conferences in May 2022:
- 05/16/2022
|
Altimmune, Inc. (ALT) CEO Vipin K. Garg on Q1 2022 Results - Earnings Call Transcript
- Altimmune, Inc. (NASDAQ:ALT ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Vipin K. Garg – President and Chief Executive Officer Richard Eisenstadt – Chief Financial Officer Scot Roberts – Chief Scientific Officer Scott M.
- 05/12/2022
|
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/12/2022
|
Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript
- Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2021 Results - Earnings Call Transcript
- 03/15/2022
|
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/15/2022
|
Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
- GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, March 15, 2022.
- 03/08/2022
|
Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
- The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.
- 01/31/2022
|
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022
- GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company's novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). The presentations will take place at the NASH-TAG Conference, which is being held January 6-8, 2022, in Park City, Utah. Details for the oral presentation are as follows:
- 01/03/2022
|
Altimmune: Changing Focus To Pemvidutide In 2022
- Altimmune is changing its focus from infectious diseases towards metabolic and liver diseases. The company is leaning on Pemvidutide for obesity, NAFLD, and NASH. So far, the dual GLP-1/glucagon receptor agonist has produced impressive results in addressing metabolic dysfunction, which evolves into chronic diseases and comorbidity.
- 01/03/2022
|
Altimmune (ALT): Richard Eisenstadt Named As CFO
- Altimmune Inc (NASDAQ: ALT) has announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021. These are the details.
- 12/13/2021
|
Altimmune to Present at Upcoming Investor and Scientific Conferences
- GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be presenting virtually at the following conferences:
- 11/22/2021
|
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2021 Results - Earnings Call Transcript
- Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2021 Results - Earnings Call Transcript
- 11/10/2021
|
Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
- Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/01/2021
|
Altimmune: Changing The Thesis
- Altimmune has been one of the top-performing stocks in our speculative portfolio. The company recently reported encouraging results from their NASH candidate, ALT-801. The market has been bullish on ALT since they announced their COVID-19 programs, but now it is time to turn our attention to ALT-801. I believe ALT-801 is their flagship.
- 10/16/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
- NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S.
- 10/15/2021
|
Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021
- GAITHERSBURG, Md., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences:
- 10/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
- New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 10/01/2021
|
Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021
- GAITHERSBURG, Md., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.
- 09/29/2021
|
H.C. Wainwright Sees Buying Opportunity In This Biotech Stock Sell Off
- H.C. Wainwright said that Altimmune Inc (NASDAQ:ALT) reported "positive" Phase 1 trial pemvidutide data, formerly known as ALT-801, in obese patients. However, shares dropped, which he sees primarily because one patient experienced elevated ALT levels that resolved after a pause in dosing.
- 09/28/2021
|
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
- Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.
- 09/28/2021
|
ALT Stock: Why It Substantially Decreased Today
- The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 19% during intraday trading today. This is why it happened.
- 09/28/2021
|
Why Altimmune Stock Is Under Pressure Today
- Safety concerns poured water on otherwise positive clinical trial results for the company's experimental weight-loss drug.
- 09/28/2021
|
See Why Altimmune Stock Plunged After Obesity Trial Data
- Altimmune Inc (NASDAQ: ALT) has announced results from a 12-week, Phase 1 trial of pemvidutide (ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist. At 12 weeks, those who received pemvidutide achieved mean weight losses of 4.9%, 10.3%, and 9.0% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, compared to 1.6% weight loss in the placebo group.
- 09/28/2021
|
Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers
- GAITHERSBURG, Md., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.
- 09/28/2021
|
Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021
- GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.
- 09/27/2021
|
Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
- GAITHERSBURG, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.
- 09/07/2021
|
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
- Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
- 08/27/2021
|
Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call Transcript
- Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 9.09% and -93.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/10/2021
|
Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
- 12-week Data Readout from ALT-801 Phase 1 Clinical Trial Expected in September
- 08/10/2021
|
Will Altimmune, Inc. (ALT) Report Negative Q2 Earnings? What You Should Know
- Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 08/03/2021
|
Wall Street Heads Into H2 With Stocks on a Streak
- Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.
- 07/02/2021
|
Why Altimmune Is Crashing Today
- The company halts development on both a COVID-19 vaccine and a drug targeting the disease.
- 06/30/2021
|
ALT Stock Price Falls Over 35%: Why It Happened
- The stock price of Altimmune Inc (NASDAQ: ALT) fell by over 35% during intraday trading. This is why it happened.
- 06/30/2021
|
ALT in Freefall After Covid-19 Vaccine Trials Scrapped
- Altimmune Inc (NASDAQ:ALT) is already taking its place as one of the worst performing stocks on the Nasdaq today, down 30.8% at $11 this morning, following news that the company dropped the development of its nasal Covid-19 vaccine after an early stage trial exhibited immune responses that missed expectations.
- 06/30/2021
|
Altimmune Stock Tanks On Double Bad News From COVID-19 Program
- Altimmune Inc (NASDAQ: ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges. The Phase 1/2 trial for T-COVID, single-dose intranasal therapeutic for early COVID-19, completed dosing in two of the three planned dose cohorts but could not fill the third cohort with patients over the age of 65 or with increased risk due to pre-existing comorbidities.
- 06/30/2021
|
Altimmune stock falls after it drops development of nasal COVID-19 vaccine
- Altimmune Inc. ALT shares dropped in the extended session Tuesday after the biotech said it was discontinuing study of a COVID-19 nasal spray vaccine because it didn't work as well as anticipated. Altimmune shares fell 33% after hours, following a 2.5% decline to close at $15.90.
- 06/29/2021
|
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial
- GAITHERSBURG, Md., June 29, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The Company also provided an update on its T-COVID Phase 1/2 clinical trial to evaluate the potential of T-COVID to prevent clinical worsening in patients with early COVID-19.
- 06/29/2021
|
ALT Stock Price Increased 16.49%: Why It Happened
- The stock price of Altimmune, Inc. (Nasdaq: ALT) increased by 16.49% yesterday. This is why it happened.
- 06/17/2021
|
Altimmune, Inc. (ALT) Soars 16.5%: Is Further Upside Left in the Stock?
- Altimmune, Inc. (ALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- 06/17/2021
|
Altimmune's Stock Trades In A Double Bottom Pattern: What's Next?
- Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was achieved at six weeks with a weekly dose of 1.8mg.
- 06/16/2021
|
Here's Why Altimmune Stock Is Surging Today
- An experimental new weight loss drug produced compelling data in an early stage clinical trial.
- 06/16/2021
|
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
- GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1/glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application.
- 06/16/2021
|
Altimmune's Intranasal COVID-19 Vaccine Candidate Neutralizes South African Variant, Animal Study Shows
- Altimmune Inc (NASDAQ: ALT) has announced new results from a preclinical study of AdCOVID, the company's vaccine candidate. Data demonstrated that the vaccine neutralized the COVID-19 B.1.351 variant that originated in South Africa.
- 05/26/2021
|
Do Options Traders Know Something About Altimmune (ALT) Stock We Don't?
- Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
- 05/25/2021
|
Altimmune: Managing A Position Around A Critical AdCOVID Readout
- Altimmune: Managing A Position Around A Critical AdCOVID Readout
- 05/25/2021
|
Altimmune: Q2 2021 Holds Large Upside Potential With 3 Trial Data Readouts And BARDA Decision
- Altimmune, Inc. is a clinical-stage biopharmaceutical company developing intranasal vaccines, immune-modulating therapies, and treatments for liver disease. Altimmune's pipeline consists of intranasal vaccines for COVID-19, anthrax, and influenza; an intranasal immune modulating therapeutic for COVID-19; and next-generation peptide therapeutics for non-alcoholic steatohepatitis and chronic hepatitis b.
- 05/24/2021
|
Altimmune, Inc.'s (ALT) CEO Vipin Garg on Q1 2021 Results - Earnings Call Transcript
- Altimmune, Inc.'s (ALT) CEO Vipin Garg on Q1 2021 Results - Earnings Call Transcript
- 05/17/2021
|
Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 2.56% and -61.74%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/17/2021
|
Altimmune to Announce First Quarter 2021 Financial Results on May 17, 2021
- GAITHERSBURG, Md., May 11, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2021 financial results on Monday, May 17, 2021.
- 05/11/2021
|
Altimmune's Intranasal COVID-19 Vaccine Candidate Shows Sterilizing Immunity After Single Dose
- Altimmune Inc (NASDAQ: ALT) has announced positive results from a preclinical study evaluating its intranasal COVID-19 vaccine candidate, AdCOVID, in a SARS-CoV-2 challenge model of infection. The results showed that a single dose of AdCOVID provided sterilizing immunity in the lungs of vaccinated mice, in contrast to the development of dense pulmonary infection and disease in the lungs of non-vaccinated mice following infection with SARS-CoV-2.
- 05/10/2021
|
Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose
- Data Show No Detectable Levels of Infectious Virus in Lungs of Vaccinated Mice Following Challenge with SARS-CoV-2
- 05/10/2021
|
Earnings Preview: Altimmune, Inc. (ALT) Q1 Earnings Expected to Decline
- Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/05/2021
|
Alternus Energy bolsters executive team by appointing industry veteran Gary Swan as CTO
- Alternus Energy Group PLC (NOTC:ALT) named industry veteran Gary Swan as its chief technical officer, as the fast-growing independent power producer expands its footprint across Europe. “Swan will join the executive management team filling a critical and strategic role for the business in supporting its goal of becoming one of the largest pan-European solar operators by 2030,” said the company.
- 04/22/2021
|
Alternus Energy Group completes €9M funding led by asset manager AVG Group Sarl
- Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, announced the recent issuance of €9 million convertible notes lead by AVG Group Sarl, a Luxembourg-based asset manager that specializes in scaling Nordic environmental, social and corporate governance (NSG), and technology. Alternus said AVG provided €8 million of the total investment, with the remainder being provided by private individuals.
- 04/12/2021
|
Wall Street starts in the red
- 10.15am: Proactive North America headlines: Genprex Inc (NASDAQ:GNPX) presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meeting Kintara Therapeutics Inc (NASDAQ:KTRA) says interim Phase 2 study data on VAL-083 shows its potential as game-changing treatment option for GBM patients Aurelius Minerals Inc (CVE:AUL) (OTCQB:AURQF) (FRA:1GA) unveils further high-grade gold results from its Aureus East project in Nova Scotia Neo Lithium Corp (CVE:NLC) (OTCQX:NTTHF) (FRA:NE2) hires consultants to help develop a sustainability program for its 3Q Lithium Project in Argentina ImagineAR Inc (CSE:IP) (OTCQB:IPNFF) (FRA:GMS1) and Liquid Avatar Technologies say rapper Jeezy to release AR-enhanced snowman logo NFT Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) (FRA:CT9) says CardiolRx safe and well tolerated in Phase I study of oral cannabidiol formulation Fury Gold Mines Limited (TSE:FURY) (NYSEAMERICAN:FURY) (FRA:AUN1) to drill "compelling" western extension targets at Eau Claire project in Quebec INDVR Brands Inc (CSE:IDVR) (OTCMKTS:CAAOF) (FRA:3YX) inks letter of intent with BevCanna to sell HONU edibles in Canada Benchmark Metals Inc (CVE:BNCH) (OTCQB:CYRTF) (FRA:87CA) posts more encouraging drill results from Lawyers underlining project's world-class mining potential Alternus Energy Group PLC (NOTC:ALT) completes €9M funding led by asset manager AVG Group Sarl QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) first drill results from Opemiska "consistent with expectations" AgraFlora Organics International Inc (CSE: AGRA) (FRA:PU31) (OTCPINK:AGFAF) subsidiary starts supplying THC Teskits to Stadapharm GmbH in Germany Else Nutrition Holdings Inc (CVE:BABY) (OTCQX:BABYF) (FRA:0YL) names two world-class experts in pediatrics nutrition and allergies to its Scientific Advisory Board Australis Capital Inc (CSE:AUSA) (OTC:AUSAF) (FRA:AC4) finds its first chief science officer in University of Alberta lead cardiologist Jason Dyck Aurania Resources Ltd (CVE:ARU) (OTCMKTS:AUIAF) (FRA:20Q) unveils sampling results from 15km long Tiria-Shimpia target at Ecuador project 9.36am: Wall Street lower The main indices on Wall Street opened in the red on Monday morning as coronavirus infections left investors feeling cautious. Shortly after the opening bell, the Dow Jones Industrial Average dropped 0.17% to 33,742 while the S&P 500 sank 0.13% to 4,123 and the Nasdaq fell 0.29% to 13,859.
- 04/12/2021
|
Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?
- The short answer: It depends.
- 04/10/2021
|
Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™
- GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate. The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers. The clinical trial was conducted with support from the Biomedical Advanced Research and Development Authority (BARDA).
- 04/01/2021
|
Alternus Energy drives continued European expansion with completion of 15MWp capacity in Romania
- Alternus Energy Group PLC (NOTC:ALT), the fast-growing pan-European independent power producer, has announced the completion of the acquisition of two additional solar parks in Romania from Renesola Power following definitive sales contracts signed between the parties in December last year. Alternus said that Lucas Est SRL situated in Dumbrava, in Prahova county western Romania, has an installed power capacity of 6 MWp.
- 03/25/2021
|
Altimmune Partners with Summit Biosciences to Produce a Multidose Nasal Spray Presentation of its AdCOVID™ Vaccine Candidate
- Metered Multidose Device Allows for Convenient and Cost-effective Vaccination Metered Multidose Device Allows for Convenient and Cost-effective Vaccination
- 03/22/2021
|
Is Altimmune a Buy?
- If you're thinking of investing in this spectacular coronavirus growth stock, now may be too late.
- 03/20/2021
|
Intranasal COVID-19 Vaccine Shows Very Promising Preclinical Results
- Altimmune Inc. (NASDAQ: ALT) is making headway in the fight against COVID-19 after the firm announced additional preclinical data in regards to its single-dose intranasal vaccine candidate, AdCOVID.
- 03/15/2021
|
ALT Stock Price Increases Over 10% Pre-Market: Why It Happened
- The stock price of Altimmune Inc (NASDAQ: ALT) has increased by over 10% pre-market. This is why it happened.
- 03/15/2021
|
Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday
- Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the stocks are moving.
- 03/12/2021
|
ALT Stock Price Increases Over 15% Pre-Market: Why It Happened
- The stock price of Altimmune Inc (NASDAQ: ALT) increased by over 15% pre-market. This is why it happened.
- 03/12/2021
|
Altimmune Shares Are Trading Higher On Expanded Manufacturing Pact With Lonza
- Altimmune Inc (NASDAQ: ALT) has expanded its previously-announced manufacturing collaboration with Lonza Group (OTCMKT: LZAGY) for AdCOVID, its single-dose intranasal COVID-19 vaccine candidate. Under the expansion, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID, at its facility near Houston, Texas.
- 03/12/2021
|
Altimmune Expands AdCOVID™ Manufacturing Collaboration with Lonza
- Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility Lonza to Commission a Dedicated Suite for Clinical and Commercial Supply of Altimmune's COVID-19 Vaccine Candidate at its Houston Facility
- 03/12/2021
|
Alternus Energy shows turn to positive EBITDA and strong revenue growth in financial results for year ended December 31, 2020
- Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing international independent power producer (IPP), headquartered in Ireland, with a focus on the midsized utility solar photovoltaic (PV) market, saw its full-year revenues increase by 77% year-on-year to €4.1 million in 2020, with Italy the largest revenue contributor at 41%, the Netherlands at 32%, and Romania 24% The group posted an EBITDA of €2.6 million as gross margins from operating parks almost doubled to €3.2 million, while corporate overhead costs reduced by 26%. Alternus Energy expects its EBITDA to increase to €18m in 2021 on completion of contracted acquisitions.
- 03/10/2021
|
Alternus Energy shows turn to positive EBITDA and strong revenue growth in financial results for the year ended December 31, 2020
- Alternus Energy Group PLC (NOTC:ALT) has reported a turn to positive EBITDA and strong revenue growth in its financial results for the year ended December 31, 2020 The company, a fast-growing international independent power producer (IPP), headquartered in Ireland, with a focus on the midsized utility solar photovoltaic (PV) market, saw its full-year revenues increase by 77% year-on-year to €4.1 million in 2020, with Italy the largest revenue contributor at 41%, the Netherlands at 32%, and Romania 24% The group posted an EBITDA of €2.6 million as gross margins from operating parks almost doubled to €3.2 million, while corporate overhead costs reduced by 26%. Alternus Energy expects its EBITDA to increase to €18m in 2021 on completion of contracted acquisitions.
- 03/10/2021
|
Altimmune to Present at Upcoming Conferences
- GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright Global Life Sciences Conference, being held Mar 9-10, 2021. Also, Altimmune's Chief Medical Officer, Dr. Scott Harris, will be giving an oral presentation at the 2021 NASH-TAG Conference, being held March 11-13, 2021.
- 03/08/2021
|
Alternus Energy harnesses the power of the sun to play a leading role in the green energy drive
- Green energy is finally going mainstream, providing predictable long-term returns, with wind and solar power part of the investment megatrend and in this Alternus Energy Group PLC (NOTC:ALT) is particularly strong in Europe. Alternus has grown in four years from being a small Romania-based operator of two solar parks with 6 MWp to becoming a pan-European independent power producer with 25 solar photovoltaic (PV) parks and a total installed capacity of 30.5 MWp in four countries.
- 03/03/2021
|
Altimmune' (ALT) CEO Vipin Garg on Q4 2020 Results - Earnings Call Transcript
- Altimmune' (ALT) CEO Vipin Garg on Q4 2020 Results - Earnings Call Transcript
- 02/25/2021
|
Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates
- Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 79.76% and 38.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 02/25/2021
|
Altimmune starts enrolling early-stage trial for its nasal spray COVID-19 vaccine candidate
- Shares of Altimmune Inc. were down 4.8% in trading on Thursday after the company said it started enrolling participants in a Phase 1 clinical trial for its COVID-19 vaccine candidate. Altimmune is developing a single-dose nasal spray vaccine.
- 02/25/2021
|
Altimmune Commences Enrollment in Phase 1 Clinical Trial of AdCOVID™ -- a Needle-Free, Single-Dose Intranasal COVID-19 Vaccine Candidate
- Nasal spray may offer room temperature distribution that could reduce logistical challenges for healthcare systems and providers
- 02/25/2021
|
Altimmune To Announce Year End 2020 Financial Results on February 25, 2021
- GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its full year 2020 financial results on Thursday, February 25th, 2021.
- 02/22/2021
|
Altimmune to start early-stage trial for its COVID-19 vaccine candidate
- Shares of Altimmune Inc. were down 4.1% in trading on Thursday, the day after the clinical-stage company said it had received regulatory approval to begin studying its COVID-19 vaccine candidate in a Phase 1 clinical trial. Altimmune said Wednesday the Food and Drug Administration had OK'ed the company's investigational new drug application for its experimental single-dose, intranasal vaccine.
- 02/18/2021
|
Why Altimmune Stock Popped Today
- The company's COVID-19 program is moving ahead.
- 02/17/2021
|
Altimmune Announces FDA Clearance of AdCOVID™ IND Application
- Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week Enrollment in Phase 1 clinical trial of single-dose, needle-free, intranasal COVID-19 vaccine candidate set to begin in the coming week
- 02/17/2021
|
3 Stocks That Could Realistically Triple Your Money in 2021
- No kidding around ... here's how they truly can.
- 01/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
- New York, New York--(Newsfile Corp. - January 11, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...
- 01/11/2021
|
2020 In Review — 9 Great (And Not-So-Great) Calls
- Technology and biotech stocks brought in more winning picks than usual, thanks partly to the strong stock market. Here are some of my best calls.
- 01/06/2021
|
Could This Under-the-Radar COVID Stock Be a Millionaire-Maker?
- This biotech just might have what it takes.
- 01/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
- NEW YORK, Jan. 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" the "Company") (NASDAQ: ALT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...
- 01/04/2021
|
3 Coronavirus Stocks Poised to Soar in 2021
- They're risky but could deliver huge returns in the new year.
- 01/03/2021
|
Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B
- Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.
- 12/31/2020
|
Why These Health Care Stocks Are Moving Today
- Altimmune (NASDAQ: ALT) shares were trading higher Wednesday after the company announced it began a multinational Phase 2 clinical trial of HepTcellTM for the treatment of chronic Hepatitis B. Altimmune is a U.S.-based, clinical-stage immunotherapeutic biotechnology company.
- 12/30/2020
|
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
- GAITHERSBURG, Md., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a novel peptide-based immunotherapeutic under development for treatment of chronic hepatitis B (CHB).
- 12/30/2020
|
Now Could Be the Perfect Time to Buy This Under-the-Radar COVID Vaccine Stock
- It's down, but not out.
- 12/30/2020
|
Altimmune: AdCOVID's Potential To Prevent Transmission May Be Key To Ending The Pandemic
- Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52. Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fundamental picture has improved with more clarity around manufacturing.
- 12/29/2020
|
How Big Is This Setback to Altimmune's COVID-19 Vaccine Candidate?
- Altimmune Inc. (NASDAQ: ALT) shares dropped on Thursday after the company announced that it had received an update from the U.S.
- 12/24/2020
|
Clinical hold on COVID-19 vaccine candidate sends Altimmune down 10% (ALT)
- Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate. AdCOVID is a single-dose intranasal COVID-19 vaccine candidate in early stages of development by Altimmune. The FDA has requested certain protocol modifications and submission of additional chemistry, manufacturing and controls data.
- 12/24/2020
|
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial
- GAITHERSBURG, Md., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company's Investigational New Drug (IND) application for AdCOVID, a single-dose intranasal COVID-19 vaccine candidate. The Agency requested certain protocol modifications and the submission of additional Chemistry, Manufacturing and Controls (CMC) data. Altimmune has responded to the Agency's clinical hold letter received on December 22, 2020 and, at this time, does not anticipate a significant impact on the overall clinical development timeline as the Company has agreed to each of the FDA's requests.
- 12/23/2020
|
Why Altimmune Stock Is Soaring Today
- Investors are excited about an analyst's bullish opinion about the biotech stock.
- 12/14/2020
|
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
- GAITHERSBURG, Md., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer of Altimmune will give an oral presentation on ALT-801, the Company's novel GLP-1/Glucagon dual receptor agonist in development for the treatment of non-alcoholic steatohepatitis (NASH.) Dr. Harris will also participate on a panel discussion on NASH treatments. The presentations will take place at the 4 th Annual NASH Summit 2020 Digital Conference , which is being held December 15-18, 2020.
- 12/11/2020
|
Altimmune: A COVID-19 Winner After All
- Share price has recently stumbled due to results of the leading vaccines. Vaccine development timeline is way behind the leading vaccines.
- 12/01/2020
|
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine
- Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.
- 11/26/2020
|
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
- Simple, single-dose nasal spray offers greater ease and comfort of administration ; positioning AdCOVID as a differentiated vaccine candidate for adults and children
- 11/25/2020
|
Altimmune to Present at Upcoming Virtual Investor Conferences
- GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:
- 11/16/2020
|
Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call Transcript
- Altimmune, Inc. (ALT) CEO Vipin Garg on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Altimmune Takes Next Step With Its COVID-19 Intranasal Vaccine
- Altimmune Inc. (NASDAQ: ALT) stepped forward on Tuesday with its vaccine candidate for COVID-19.
- 11/10/2020
|
Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
- AdCOVID , a Single-dose Intranasal Vaccine for COVID-19 is Designed to Generate a Broad Immune Response Against COVID-19 with the Unique Ability to Promote Nasal Mucosal Immunity
- 11/10/2020
|
Altimmune Announces Third Quarter 2020 Financial Results and Provides a Business Update
- GAITHERSBURG, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2020 and provided a business update.
- 11/09/2020
|
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
- GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.
- 11/03/2020
|
Arena Wins Special Situations Manager of the Year at Alt Credit Fund Intelligence US Performance Awards 2020
|
Singles' Day Set To Propel Alibaba Higher (NYSE:BABA)
- Mainland and Hong Kong markets started the week bullish with the anticipation of positive policy developments from the Chinese president's tour of southern China.
- 10/19/2020
|
Mid-Day Market Update: Gold Down 2%; Medigus Shares Spike Higher
- Midway through trading Tuesday, the Dow traded down 0.25% to 28,766.88 while the NASDAQ rose 0.19% to 11,899.41. The S&P also fell, falling 0.28% to 3,524.36.
The U.S. has...
- 10/13/2020
|
Seeking Yield With Safety
- Lipper categories with low risk and moderate to high yields are listed. Top-ranked funds within the categories are listed.
- 10/12/2020
|
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 24)
Beigene Ltd (NASDAQ: BGNE...
- 09/25/2020
|
India OTT Video Services Market, Competition, Forecast & Opportunities, 2026 - ResearchAndMarkets.com
|
Altimmune: The Late Bloomer Of The COVID-19 Biotech World, The Best Is Yet To Come (NASDAQ:ALT)
- I am bullish on Altimmune because of their two COVID-19 programs, T-COVID and AdCOVID. Specifically, T-COVID is reminiscent of a Tamiflu, but for COVID-19.
- 09/17/2020
|
David Axelrod, Karl Rove and Matt VanDyke to Speak at TVB Alt Forward 2020 Conference
- TVB’s 2020 Alt Forward Conference will be unlike any before - this year’s conference will be a fully virtual, multi-dimensional experience, taking pla
- 09/16/2020
|
Coronavirus Vaccine Roundup, Early September
- Taking a looking at the COVID-19 vaccine development landscape across various classes, including viral vectors, genetic vaccines, recombinant protein vaccines, attenuated virus vaccines, inactivated virus vaccines, and virus-like particles.
- 09/04/2020
|
9 Reasons Why The Race For Major COVID-19 Vaccine Revenues Has Greatly Narrowed
- The huge amount of Operation Warp Speed funding for its six vaccines has helped them become somewhat dominant leaders in the race for a sizable share of the market.
- 09/02/2020
|
Altimmune COVID Update, And Other News: The Good, Bad And Ugly Of Biopharma
- Altimmune provides positive updates for AdCOVID. Ovid reports positive Phase 2 ELEKTRA study data.
- 08/27/2020
|
Altimmune Announces Second Quarter 2020 Financial Results and Provides a Business Update
- GAITHERSBURG, Md., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020 and provided a business update. “We are pleased with Altimmune’s progress during 2020 as we have launched two new product candidates for COVID-19, progressed our NASH candidate toward clinical testing and forged strategic alliances with Vigene Biosciences and DynPort Vaccine Company” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “With the support of our shareholders, we now have more than $200 million of cash and investments on hand to drive continued development of our product pipeline.”Recent Highlights * Received gross proceeds of $199.4 million from a public offering, warrant exercises and ATM sales since Q1 2020 Since the first quarter, the Company has received $132.2 million in gross proceeds from a public offering of common stock and pre-funded warrants, $40.9 million from warrant exercises and $26.3 million in gross proceeds from ATM sales. The cash received will be used primarily for the development of AdCOVID and T-COVID, including scale up of manufacturing and advanced clinical trials; the continued development of ALT-801, a dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH), including the first-in-human trial later this year; and for capital expenditures and general working capital purposes. * Announced positive preclinical results for AdCOVID The Company announced positive results from the preclinical studies of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID. The studies, which were conducted in collaboration with the University of Alabama at Birmingham (UAB), showed strong serum neutralizing activity and potent mucosal immunity in the respiratory tract. The induction of mucosal IgA antibody in the respiratory tract may be necessary to block both infection and transmission of the virus to prevent further spread of COVID-19. Based on these findings, the Company has initiated manufacturing of AdCOVID and plans to advance the vaccine candidate to a Phase 1 safety and immunogenicity study in Q4 of this year. * Announced manufacturing agreement with Vigene Biosciences for AdCOVID The Company announced that it has entered into an agreement with Vigene Biosciences to manufacture AdCOVID, the Company’s single-dose intranasal vaccine candidate for COVID-19. Vigene, a Rockville, Maryland-based award-winning Contract Development and Manufacturing Organization, specializes in viral vectors and will deploy its capabilities to manufacture AdCOVID. Following recent positive pre-clinical data, the Company plans to start a Phase 1 clinical trial of AdCOVID in Q4 2020. * Formed teaming agreement with DynPort Vaccine Company for AdCOVID The Company announced that it has entered into a teaming agreement with DynPort Vaccine Company (DVC), a General Dynamics Information Technology (GDIT) company, to coordinate U.S. Government funding efforts and, if successful, to provide program management, drug development activity integration, and regulatory support for AdCOVID. * Initiated T-COVID program and received $4.7 million award from the DoD to fund Phase 1/2 clinical trial The U.S. Food and Drug Administration (FDA) authorized the Company to proceed with a Phase 1/2 clinical trial of T-COVID, an investigational therapeutic agent for the treatment of early COVID-19. The EPIC Trial (Efficacy and Safety of T-COVID in the Prevention of Clinical Worsening in COVID-19) is being funded through a $4.7 million competitive award from the U.S. Army Medical Research & Development Command (USAMRDC) and Department of Defense (DoD) working in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium. Altimmune recently initiated multiple clinical sites across the United States and expects that enrollment will commence imminently. * Completed enrollment in Phase 1b clinical trial of NasoShield The Company completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised. At the conclusion of the Phase 1b NasoShield trial, BARDA will have the option of exercising the remaining contract options valued at approximately $105 million to enable Phase 2 development. * Advanced IND-enabling activities for ALT-801 GLP-1/glucagon dual receptor agonist for NASH The Company has successfully completed the in-life portion of the safety and toxicological assessment of ALT-801 and is manufacturing the clinical trial material for the first-in-human trial, expected to start in Q4 2020. The single and multiple ascending dose trial will be conducted in Australia and will evaluate the safety and activity of ALT-801 in overweight and obese volunteers. Data from that study, including validation of the compound’s weight loss and liver fat-reducing effects, is expected to read out in the spring of 2021. * Received HepTcell IND clearance for Phase 2 trial The FDA cleared the Company’s Investigational New Drug (IND) application to conduct a Phase 2 trial of HepTcell, a peptide-based immunotherapeutic for the treatment of chronic hepatitis B (HBV). The Company is also filing CTAs in Canada and three European countries. Altimmune plans to initiate the multinational trial in Q4 of this year, subject to an ongoing assessment of the impact of COVID-19 on study conduct.Financial Results for the Second Quarter Ended June 30, 2020 * The Company had cash, cash equivalents and short-term investments of $80.3 million at June 30, 2020. Subsequent to the quarter ended June 30, 2020, the Company received approximately $136.2 million in net proceeds from the public offering of its common stock, warrant exercises, and ATM sales. * Revenue was $0.7 million for the quarter ended June 30, 2020 compared to $1.6 million in the prior year period. The change was primarily due to a decrease in billings under the Company’s U.S. government contracts due to timing of manufacturing and clinical trials for the NasoShield program. * Research and development expenses were $16.5 million for the quarter ended June 30, 2020 compared to $2.9 million in the prior year period. The increase was primarily attributable to an increase in the contingent liability for stock-based milestone payments associated with the acquisition of ALT-801; development costs for IND-enabling preclinical studies for ALT-801; and development costs for the COVID-19 programs. These increases were partially offset by decreased spend on the NasoShield program. * General and administrative expenses were $2.5 million for the quarter ended June 30, 2020 compared to $2.2 million in the prior year period. The increase is attributable to higher employee compensation and legal costs. * Income tax benefit was $1.6 million for the three months ended June 30, 2020, as compared to zero for the same period in 2019. The increase is attributable to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) passed on March 27, 2020 which made temporary changes regarding the utilization and carry back of net operating losses. The Company intends to file a tax refund claim with the Internal Revenue Service reflecting a partial refund of its 2016 tax liability by carrying back net operating losses arising during the three and six months ended June 30, 2020. * Net loss attributed to common stockholders for the quarter ended June 30, 2020 was $16.8 million, or $0.94 net loss per share, compared to $3.4 million in the prior year, or $0.26 net loss per share. The difference in net loss is primarily attributable to higher research and development expenses, lower revenue, offset by an increase in income tax benefit.Conference Call Information Altimmune will host a conference call to discuss the company’s second quarter results and other business information. Date: Wednesday, August 12, 2020 Time: 8:30 am Eastern Time Domestic: 877-423-9813 International: 201-689-8573 Conference ID: 13706947 Webcast: http://public.viavid.com/index.php?id=140748 Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The company has used, and intends to continue to use, the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
- 08/11/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Altimmune Completes Enrollment in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
- GAITHERSBURG, Md., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has completed enrollment in its Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. With this milestone, the data readout for the Day 28 immunogenicity endpoint remains on target for Q4 2020. The clinical trial has enrolled 42 evaluable healthy subjects to receive intranasally administered NasoShield or placebo and be followed for 6 months following dosing. The primary immunogenicity readouts are the serum antibody response to protective antigen and toxin-neutralizing antibody titer 28 and 56 days after dosing. As with Altimmune’s other vaccine programs, stimulation of a mucosal IgA immune response in the nasal cavity will also be assessed as a potential additional benefit to other immunologic responses. Nasal mucosal immunity, which can play an important role in the body’s defense against respiratory diseases, is best stimulated by the nasal route of vaccine administration.The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised. At the conclusion of the Phase 1b NasoShield trial, BARDA will have the option of exercising the remaining contract options valued at approximately $105 million to enable Phase 2 development.NasoShield has the potential to be a convenient and simple alternative to the current approved multi-dose anthrax vaccine, as it is intended to confer protection after a single intranasal dose instead of the three-injection regimen required by the only licensed vaccine. Intranasal dosing provides the potential to be administered rapidly and without the need for needles, syringes or trained healthcare personnel in the event of an anthrax incident. In addition, NasoShield’s expected room temperature stability profile may allow for broad distribution of the vaccine without the need for expensive cold-chain logistics, such as refrigeration or freezing.Earlier this quarter, the Company reported positive preclinical data on AdCOVID, a single dose intranasal COVID-19 vaccine candidate which is derived from the same replication-deficient adenovirus 5 vaccine platform technology as NasoShield. In these preclinical studies performed in collaboration with the University of Alabama at Birmingham (UAB), AdCOVID elicited a strong systemic antibody response against the receptor-binding domain (RBD) in mice, stimulated serum viral neutralization titers, and activated a 29-fold induction of mucosal IgA against SARS-CoV-2 in bronchoalveolar fluid of vaccinated mice. The Company plans to initiate a Phase 1 clinical trial of AdCOVID during the fourth quarter of 2020.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the initiation and timing of the NasoShield clinical trial and receipt of data from the clinical trial in 2020, the potential for additional funding from BARDA, the potential immunization effects of NasoShield, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; funding delays, reductions in or elimination of U.S. government funding and/or non-renewal of expiring funding under the Company’s agreement with BARDA; the Company’s ability to satisfy certain technical milestones under the Company’s contracts with BARDA that would entitle the Company to receive additional funding over the period of the agreement; the Company’s ability to obtain potential regulatory approvals on the timelines anticipated, or at all; and the Company’s ability to expand its pipeline of products and the success of future product advancements, including the success of future clinical trials, and the Company’s ability to commercialize its products. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 and quarterly report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC, which are available at www.sec.gov.Investor Contacts: Will Brown Ashley R. Robinson Chief Financial Officer LifeSci Advisors, LLC Phone: 240-654-1450 617-430-7577 wbrown@altimmune.com arr@lifesciadvisors.com Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com
- 08/07/2020
|
Altimmune to Announce Second Quarter 2020 Financial Results on August 12
- GAITHERSBURG, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the three and six months ended June 30, 2020 and its business outlook before the market open and host a conference call on Wednesday, August 12, 2020. Conference Call Details Date:Wednesday, August 12 Time:8:30 am Eastern Time Domestic:877-423-9813 International:201-689-8573 Conference ID:13706947 Webcast:http://public.viavid.com/index.php?id=140748 About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Investor Contacts: Will BrownAshley R. Robinson Chief Financial OfficerLifeSci Advisors, LLC Phone: 240-654-1450617-430-7577 wbrown@altimmune.comarr@lifesciadvisors.com Media Contacts: Warren Rizzi Sard Verbinnen & Co. Phone: 212-687-8080 altimmune-svc@sardverb.com
- 08/05/2020
|
Biotech Bonanza - Second Half Outlook
- Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest creates an ideal environment for biotechs to continue outperforming the market.
- 07/28/2020
|
Altimmune Announces Manufacturing Agreement with Vigene Biosciences for AdCOVID™, its Single Dose Intranasal Vaccine Candidate for COVID-19
- GAITHERSBURG, Md., July 22, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company has entered into an agreement with Vigene Biosciences (“Vigene”) to manufacture AdCOVIDTM, Altimmune’s single-dose intranasal vaccine candidate for COVID-19. Vigene, a Rockville, Maryland-based award-winning Contract Development and Manufacturing Organization (CDMO), specializes in viral vectors and will deploy its capabilities to manufacture AdCOVID. Following recent positive pre-clinical data, Altimmune plans to start a Phase 1 clinical trial of AdCOVID in Q4 2020. “Vigene is a fantastic partner to advance AdCOVID into Phase 1 clinical testing and beyond,” said Dr. Vipin K. Garg, President and CEO of Altimmune. Dr. Garg continued, “We believe Vigene’s deep experience in viral vector production and their collaborative, client focused approach will help facilitate Altimmune’s timeline for clinical development of AdCOVID.”“With our new state-of-the-art manufacturing facility and our expertise in viral vector production, we are well positioned to support Altimmune in their COVID-19 vaccine development efforts,” said Dr. Zairen Sun, Vigene’s President and CEO. “In addition to our existing facility, we are in the process of expanding our capacity so that we can support Altimmune beyond clinical development into commercial scale manufacturing.”Altimmune is also initiating scale up of manufacturing of its AdCOVID vaccine for advanced clinical trials and commercial production. The Company is actively engaged in discussions with additional strategic manufacturing partners with the goal of producing at least 100 million doses of AdCOVID in 2021.AdCOVID is an intranasal vaccine candidate designed to block viral infection and to provide protection against viral spread through stimulation of both mucosal and systemic neutralizing antibodies (IgA and IgG) as well as cell-mediated immunity. By stimulating mucosal immunity in the nasal cavity, a key point of entry and replication for SARS-CoV-2, AdCOVID has the potential to defend against both infection in the recipient as well as spread of the virus to others. Intranasal administration can also be accomplished more simply than an injection and may eliminate the need for highly trained medical personnel. In addition, since it is expected to have extended stability at room temperature, AdCOVID may avoid the need for costly cold chain logistics.In preclinical studies conducted in collaboration with the University of Alabama at Birmingham (UAB), AdCOVID stimulated both strong serum neutralizing activity and potent mucosal immunity (IgA) in the respiratory tract. Additionally, vaccination of mice with AdCOVID caused the rapid recruitment of immune cells into the respiratory tract, draining lymph nodes and spleen consistent with induction of potent local and systemic immunity. Increases in CD8+ and CD4+ T cells, dendritic cells and NK cells were observed in the respiratory tract, and germinal center and memory B cells as well as T follicular helper cells were observed in regional lymph nodes and the spleen. Importantly, the latter cell types have been associated in prior vaccine development research with long-lived antibody responses.About Vigene Biosciences Vigene Biosciences, Inc. is an award-winning leader in viral vector-based gene delivery for both life science research, gene therapy and cell therapy purposes. Headquartered in Rockville, Maryland, Vigene features 10 fully equipped GMP clean room suites for AAV, lentivirus, retrovirus, adenovirus and plasmids GMP production, respectively. In addition, Vigene also develops and owns a panel of intellectual properties including proprietary high productivity cell lines (suspension and adherent cells) for viral vector packaging and patents for increasing viral vector packaging efficiency. Vigene offers FDA and EMA compliant cGMP production for viral vector and plasmid production with the mission of making gene therapy affordable. For more information on Vigene, please visit www.vigenebio.com.About Altimmune Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating treatment for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the initiation and timing of the AdCOVID Phase 1 clinical trial in Q4 2020, the initial immunogenicity results of our AdCOVID preclinical studies, the potential immunization effects of AdCOVID, our ability to manufacture 100 million doses of AdCOVID in 2021, and the prospects for regulatory approval, commercializing or selling AdCOVID or any of our other product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; the Company’s ability to secure manufacturing approval from its SARS-CoV-2 cell licensor on the timelines anticipated; the Company’s ability to secure additional manufacturing partners; the Company’s ability to obtain potential regulatory approvals on the timelines anticipated, or at all; and the Company’s ability to expand its pipeline of products and the success of future product advancements, including the success of future clinical trials, and the Company’s ability to manufacture and commercialize its products. Further information on the factors and risks that could affect the Company's business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 and quarterly report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC, which are available at www.sec.gov.Contacts Altimmune: Will Brown Ashley R. Robinson Chief Financial Officer Managing Director LifeSci Advisors Phone: 240-654-1450 Phone: 617-430-7577 Email: wbrown@altimmune.com Email: arr@lifesciadvisors.com Vigene Biosciences: Jeffrey Hung, Ph.D. Chief Commercial Officer 301-251-6638 jhung@vigenebio.com
- 07/22/2020
|
Altimmune Announces Closing of $132 Million Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option
- GAITHERSBURG, Md., July 16, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that its previously announced underwritten public.
- 07/16/2020
|
My COVID-19 Vaccine Report Card
- The COVID-19 pandemic has created a gold-rush on vaccine stocks. Many of the small-cap biotech and pharmaceutical companies have experienced 1000%+ gains as investors speculative who will be first.
- 07/16/2020
|
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
Altimmune Inc (NASDAQ: ALT...
- 07/15/2020
|
Altimmune Announces Pricing of a Public Offering of $115 Million of Common Stock and Pre-Funded Warrants
- GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,369,564 shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase 1,630,436 shares of its common stock at an exercise price of $0.0001 per share. The public offering price of each share of common stock is $23.00 and the public offering price of each pre-funded warrant is $22.999 per underlying share. In addition, Altimmune has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. This offering is expected to close on or about July 16, 2020, subject to satisfaction of customary closing conditions. Altimmune expects to receive gross proceeds of $115.0 million, before deducting underwriting discounts and offering expenses (without giving effect to any exercise of the underwriters’ option to purchase additional shares, if any). Altimmune anticipates using the net proceeds from the offering for general corporate purposes, which may include, but are not limited to, scale up of manufacturing and advanced clinical trials of AdCOVID, a single dose intranasal COVID-19 vaccine candidate; the continued development of ALT-801, its dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH), including manufacturing and clinical trials; and for capital expenditures and working capital.Jefferies, Evercore ISI and Piper Sandler are acting as joint book-running managers for the offering. Roth Capital Partners is acting as co-manager for the offering.The securities described above are being offered by Altimmune pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with and became effective by rule of the Securities and Exchange Commission (SEC) on April 12, 2019. A preliminary prospectus supplement and accompanying prospectus related to the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), an intranasal immune modulating treatment for COVID-19 (T-COVIDTM) and intranasal vaccines (AdCOVIDTM, NasoShield™ and NasoVAX™).Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Altimmune’s size, completion and use of proceeds relating to the public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the satisfaction of the closing conditions for the public offering. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Altimmune’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 27, 2020, Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as filed with the SEC on May 13, 2020, the preliminary prospectus supplement related to the public offering filed with the SEC on July 13, 2020 and other filings that Altimmune’s may make with the SEC in the future. Any forward-looking statements contained in this press release represent Altimmune’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Altimmune explicitly disclaims any obligation to update any forward-looking statements.Contacts Will Brown Ashley R. Robinson Chief Financial Officer Managing Director LifeSci Advisors Phone: 240-654-1450 Phone: 617-430-7577 Email: wbrown@altimmune.com Email: arr@lifesciadvisors.com
- 07/14/2020
|
Vaccine Makers BioNTech, Moderna, And Novavax Set To Run Higher
- Stocks Analysis by Harry Boxer covering: KB Home, Vaxart Inc, Novavax Inc, Altimmune Inc. Read Harry Boxer's latest article on Investing.com
- 07/14/2020
|
Altimmune Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- GAITHERSBURG, Md., July 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock. Altimmune also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock plus the shares of common stock underlying the pre-funded warrants sold in connection with the public offering. All of the securities in the offering will be sold by Altimmune. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Altimmune anticipates using the net proceeds from the offering for general corporate purposes, which may include, but are not limited to, scale up of manufacturing and advanced clinical trials of AdCOVID, a single dose intranasal COVID vaccine candidate; the continued development of ALT-801, its dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH), including manufacturing and clinical trials; and for capital expenditures and working capital.Jefferies, Evercore ISI and Piper Sandler are acting as joint book-running managers for the offering. Roth Capital Partners is acting as co-manager for the offering.The securities described above are being offered by Altimmune pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed with and became effective by rule of the Securities and Exchange Commission (SEC) on April 12, 2019. A preliminary prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Departments, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at (877) 821-7388; or by email at Prospectus_Department@Jefferies.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, New York, NY 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN, 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@psc.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.About AltimmuneAltimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and intranasal vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), an intranasal immune modulating treatment for COVID-19 (T-COVID™) and intranasal vaccines (AdCOVID™, NasoShield™ and NasoVAX™).Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Altimmune’s intention, timing and use of proceeds relating to the proposed public offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “proposed” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as the intended offering terms, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Altimmune’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 27, 2020, Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, as filed with the SEC on May 13, 2020, the preliminary prospectus supplement related to the public offering to be filed with the SEC on or about the date hereof and other filings that Altimmune’s may make with the SEC in the future. Any forward-looking statements contained in this press release represent Altimmune’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Altimmune explicitly disclaims any obligation to update any forward-looking statements. Contacts Will Brown Ashley R. Robinson Chief Financial Officer Managing Director LifeSci Advisors Phone: 240-654-1450 Phone: 617-430-7577 Email: wbrown@altimmune.com Email: arr@lifesciadvisors.com
- 07/13/2020
|
Altimmune and the University of Alabama at Birmingham (UAB) Announce Positive Preclinical Results for Intranasal COVID-19 Vaccine Candidate, AdCOVID™
- GAITHERSBURG, Md., July 13, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from the preclinical studies of.
- 07/13/2020
|
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 9)
Affimed NV (NASDAQ: AFMD)...
- 07/10/2020
|
Why Altimmune's Stock Is Trading Higher Today
- Altimmune (NASDAQ: ALT) shares are trading higher on Thursday after the company signed a teaming agreement with DynPort vaccine company on U.S. government funding efforts for its AdCOVID vaccine candidate.Altimmune is a U.S.-based clinical-stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of liver diseases.The firm's product candidates include NasoVAX, HepTcell, SparVax-L, and NasoShield. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.Altimmune shares were trading up 13.98% at $19.41 on Thursday during the time of publication. The stock has a 52-week high of $22.92 and a 52-week low of $1.51.See more from Benzinga * Why Roku's Stock Is Trading Higher Today * Bed Bath & Beyond Reports Q1 Earnings Miss After Pandemic Store Closures * Why Snap's Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/09/2020
|
Altimmune Signs Teaming Agreement with DynPort Vaccine Company on U.S. Government Funding Efforts for its COVID-19 Vaccine Candidate, AdCOVID™
- GAITHERSBURG, Md., July 09, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into a teaming agreement with.
- 07/09/2020
|
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 8)
Akero Therapeutics Inc (...
- 07/09/2020
|
What Type Of Shareholders Make Up Altimmune, Inc.'s (NASDAQ:ALT) Share Registry?
- If you want to know who really controls Altimmune, Inc. (NASDAQ:ALT), then you'll have to look at the makeup of its...
- 07/08/2020
|
6 Stocks That Could Pop Higher
- Stocks Analysis by Harry Boxer covering: BioCryst Pharmaceuticals Inc, Cytokinetics Inc, Vaxart Inc, Novavax Inc. Read Harry Boxer's latest article on Investing.com
- 07/08/2020
|
Global Biodefense Market (2020 to 2030) - by Product, Sales Channel, Application, and Region - ResearchAndMarkets.com
|
Leaf Group, Forma Therapeutics See Activist Action
- Oak Investment Partners disclosed a large stake in digital-content provider Leaf Group. Forma Therapeutics said it owns more than nine million shares of biopharmaceutical firm Forma.
- 07/02/2020
|
'Disaster' as 350 elephants mysteriously drop dead near waterholes in Africa
- AT LEAST 350 elephants have mysteriously dropped dead near waterholes in Africa… and nobody knows why it’s happened. The gentle giants reportedly died from unknown causes and aerial sho…
- 07/02/2020
|
Altimmune Announces Dosing of First Patient in Phase 1b Clinical Trial of NasoShield™, a Single Dose Intranasal Anthrax Vaccine Candidate
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced dosing of the first patient in the Company’s Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised. “NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and three-dose injectable anthrax vaccine regimens”, said Vipin K. Garg, Ph.D., President and CEO of Altimmune.
- 06/30/2020
|
Coronavirus Vaccine Update, June 29
- Genetic vaccines take DNA or RNA coding for coronavirus proteins and inject that directly into the bloodstream. Novavax has been raising significant amounts of
- 06/30/2020
|
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
- The following is a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)
ADC Therapeutics SA (...
- 06/30/2020
|
Altimmune Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID™ in Outpatients with Early COVID-19
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD).
- 06/29/2020
|
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 25)
Brainstorm Cell...
- 06/26/2020
|
Merck : FDA Approves Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation | MarketScreener
|
iShares Diversified Alternatives Trust (NYSEARCA:ALT) Rating Lowered to Sell at Zacks Investment Research
- iShares Diversified Alternatives Trust (NYSEARCA:ALT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Monday, Zacks.com reports. According to Zacks, “Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention […]
- 06/24/2020
|
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation
- FDA Approves Merck’s KEYTRUDA® for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC).
- 06/24/2020
|
Altimmune Announces IND Clearance for a Phase 2 Trial of HepTcell™ Immunotherapeutic for the Treatment of Chronic Hepatitis B
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to conduct a Phase 2 trial of HepTcell, a peptide-based immunotherapeutic for the treatment of chronic hepatitis B. The Company is also filing clinical trial applications in Canada, Spain, Germany and the United Kingdom. Altimmune plans to initiate a multinational trial in Q4 of this year, subject to an ongoing assessment of the impact of COVID-19 on study conduct. “We believe that HepTcell could also be the key immunotherapy component of a future anti-HBV combination regimen to help break immune tolerance and achieve a functional cure.”
- 06/22/2020
|
Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10)
- KEYTRUDA® Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- 06/22/2020
|
Altimmune’s Largest Investor Sees Potential Coronavirus Vaccine, Buys More Stock
- Venrock Healthcare Capital paid $11.3 million for 1.5 million more Altimmune shares on June 15. It was buying shares of the biopharmaceutical firm in late May, as well.
- 06/21/2020
|
COVID-19 Impact and Recovery Analysis - Global Biodefense Market 2020-2024 | Evolving Opportunities with Alexeter Technologies LLC and Alnylam Pharmaceuticals Inc. | Technavio
- The Global Biodefense Market will grow by $ 3.22 billion during 2020-2024
- 06/19/2020
|
Are Options Traders Betting on a Big Move in Altimmune (ALT) Stock?
- Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
- 06/17/2020
|
How to buy Altimmune shares from Australia | 16 Jun price $7.68
- Ever wondered how to buy shares in Altimmune in Australia? We explain how and compare the best share trading platforms.
- 06/16/2020
|
NASDAQ Briefly Tops 10K and Finishes with New High
- NASDAQ Briefly Tops 10K and Finishes with New High
- 06/10/2020
|
NASDAQ Reaches Record High, S&P Positive for 2020
- NASDAQ Reaches Record High, S&P; Positive for 2020
- 06/09/2020
|
Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma
- Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) in Patients with Advanced or Metastatic Urothelial Carcinoma
- 06/09/2020
|
Altimmune Launches Clinical Trial of T-COVIDTM, an Investigational Intranasal Immune Modulator for the Treatment of Patients with Early COVID-19
- Company to host conference call on Monday, June 1, 2020 at 8:30 a.m. GAITHERSBURG, Md., June 01, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has authorized the Company to proceed with a clinical trial of T-COVID, an investigational agent for the treatment of early COVID-19. Patient enrollment in the Phase 1/2 clinical trial is expected to commence in June, with data readout anticipated in Q4 2020.
- 06/01/2020
|
COVID-19 Drug and Vaccine Pipeline Status Report - Research; Pre-Clinical; Phase 1, 2 & 3 Drug Candidates - ResearchAndMarkets.com
|
ER doctor: 12-18 month coronavirus vaccine timeline 'is extremely optimistic'
- As the fallout from the coronavirus pandemic continues, the search for a vaccine is not slowing down.
- 05/28/2020
|
6 Stock Charts to Watch: ALT, CAR, MGM, JETS, OVID, VLO
- Stocks Analysis by Harry Boxer covering: SPDR S&P 500, Ballard Power Systems Inc, MGM Resorts International, Darden Restaurants Inc. Read Harry Boxer's latest article on Investing.com
- 05/27/2020
|
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
- 05/21/2020
|
Is the Options Market Predicting a Spike in Altimmune (ALT) Stock?
- Investors need to pay close attention to Altimmune (ALT) stock based on the movements in the options market lately.
- 05/15/2020
|
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 14)
Allogene Therapeutics Inc (...
- 05/15/2020
|
6 Stocks To Watch: Co-Diagnostics, Inovio, Progyny, Translate Bio, Upwork...
- Stocks Analysis by Harry Boxer covering: Overstockcom Inc, PGT Innovations Inc, Creative Realities Inc, United Natural Foods Inc. Read Harry Boxer's latest article on Investing.com
- 05/14/2020
|
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
- GAITHERSBURG, Md., May 13, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31,.
- 05/13/2020
|
Altimmune Announces First Quarter 2020 Financial Results and Provides a Business Update
- GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the quarter ended March 31, 2020 and provided a business update. “Throughout 2020 we have put significant effort into developing our pipeline; from advancing our vaccine candidates, AdCOVID and Nasoshield, to IND enabling studies and manufacturing for ALT-801 and HepTcell,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “Based on our progress, we are poised for a data-rich year, with the expected initiation of NasoShield, ALT-801 and AdCOVID clinical trials.”Recent Highlights * Preclinical testing commences on COVID-19 vaccine candidate, AdCOVID In collaboration with the University of Alabama at Birmingham (UAB), we have commenced preclinical testing of candidates for our COVID-19 vaccine, AdCOVID. AdCOVID is being developed as a single dose, intranasal vaccine that is designed to activate multiple arms of the immune system including humoral (antibodies), cellular (T-cell) and mucosal immunity. Our platform vaccine technology is ideally suited for pandemic use and based on Phase 2 clinical data obtained with our influenza vaccine candidate, NasoVAX, AdCOVID is expected to meet or exceed key attributes of the World Health Organization’s (WHO) preferred Target Product Profile (TPP) for a COVID-19 vaccine: WHO Preferred Attribute (TPP)1AdCOVID Expected Attribute (based on NasoVAX data) Single doseSeroprotection with single dose administration Rapid onset of protectionStrong serological response at 2 weeks Immunity lasting at least 1 yearSerological response unchanged at 400 days Non-injectedIntranasal administration Temperature stabilityAt least 3 months at 25oC in a liquid formulation Ability to provide at low costHigh yield, scalable manufacturing process 1https://www.who.int/blueprint/priority-diseases/key-action/WHO_Target_Product_Profiles_for_COVID-19_web.pdf It is expected that the studies at UAB will confirm the broad and robust immune response of the vaccine technology and identify the best vaccine candidate for clinical development. The Company is finalizing manufacturing plans, and intends to conduct a Phase 1 clinical trial of AdCOVID in Q4 of this year. * NasoShield Phase 1b trial expected to begin in June The Phase 1b clinical trial of Nasoshield, our single-dose intranasal anthrax vaccine candidate, is expected to commence in June of this year. A data readout is expected in November 2020 and will inform BARDA’s decision to exercise the remaining options on the contract. The NasoShield program is funded through a contract with BARDA (HHSO100201600008C), with a total potential value of $133.7 million if all options in the contact are exercised. NasoShield is the only single dose vaccine candidate for anthrax currently funded by BARDA. NasoShield’s intranasal route of administration allows for administration without injections and its stability at room temperature may permit distribution without cold chain. * ALT-801 manufacturing commences We have commenced manufacturing of the clinical trial material for ALT-801, our dual GLP-1/glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH). The combination of GLP-1 and glucagon agonism within the same molecule is ideal for treating obesity, the basic underlying cause of NASH. In animal studies, ALT-801 resulted in more than twice the weight loss of semaglutide and greater improvement in histologic measures of fatty liver, liver inflammation, and fibrosis. The Company is currently completing toxicology studies that will enable the commencement of clinical trials in Q4 2020. * HepTcell manufacturing completed, IND filing expected next week We have completed manufacturing for HepTcell, our synthetic peptide immunotherapeutic candidate designed to break immune tolerance in patients with chronic hepatitis B (HBV) infection. The completion of this activity enables the filing of our IND, which is expected next week. The planned Phase 2 trial is a 6-month course of treatment in chronically infected HBV patients in both North America and Europe. Considering this is a multi-site, multi-national study with a long duration of treatment, the Company is actively monitoring the COVID-19 situation and will determine the actual start date of this trial once more information becomes available. * Diane Jorkosky, M.D. joins Altimmune Board of Directors Former Pfizer and GSK executive, Diane Jorkasky, M.D., joined Altimmune’s Board of Directors on May 11, 2020. Dr. Jorkasky’s experience in the biopharmaceutical industry, academia and as a physician bring valuable experience to Altimmune.Financial Results for the Quarter Ended March 31, 2020 * The Company had cash, cash equivalents and short-term investments of $33 million at March 31, 2020. * The Company’s income tax receivable increased $3.4 million primarily due to an expected cash tax refund claim of $2.9 million with the Internal Revenue Service reflecting a partial refund of its 2016 tax liability by carrying back its 2019 and 2018 net operating losses. Additionally, the Company estimates it will claim $0.36 million related to net operating losses arising during the three months ended March 31, 2020. The expected refund claims are due to the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) passed on March 27, 2020 which made temporary changes regarding the utilization and carry back of net operating losses. * Revenue was $2.2 million for the quarter ended March 31, 2020 compared to $3 million in the prior year period. The change was due primarily to a decrease in billings under the Company’s U.S. government contracts due to timing of manufacturing and clinical trials for the NasoShield program. * Research and development expenses were $7.2 million for the quarter ended March 31, 2020 compared to $3.2 million in the prior year period. The increase was primarily attributable to development costs for IND-enabling preclinical studies for ALT-801; an increase in the contingent liability for stock-based milestone payments associated with the acquisition of ALT-801; and an increase in employee compensation and professional services. These increases were offset by decreased spend for NasoShield. * General and administrative expenses were $2.3 million for the quarter ended March 31, 2020 compared to $2.1 million in the prior year period. The increase is attributable to higher employee compensation and legal costs. * Other income (expense) was $0.2 million for the quarter ended March 31, 2020 compared to $0.2 million in the prior year. Income for both periods is primarily attributable to interest earned on cash and investment balances. * Income tax benefit was $3.2 million for the three months ended March 31, 2020, as compared to zero for the same period in 2019. The increase is attributable to the income tax refund claims described above related to the “CARES Act”. * Net loss attributed to common stockholders for the quarter ended March 31, 2020 was $3.9 million, or ($0.26) per share, compared to $2.6 million in the prior year, or ($0.27) per share. The difference in net loss is primarily attributable to higher research and development expenses, lower revenue, offset by an increase to income tax benefit.Conference Call InformationAltimmune will host a conference call to discuss the company’s first quarter results and other business information.Date:Thursday, May 14, 2020 Time:8:30 am Eastern Time Domestic:855-327-6837 International:631-891-4304 Conference ID:10009533 Webcast:http://public.viavid.com/index.php?id=139687 Following the conclusion of the call, the webcast will be available for replay on the Investor Relations page of the Company’s website at www.altimmune.com. The company has used, and intends to continue to use, the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.About Altimmune Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver disease, immune modulating therapies and vaccines. Our diverse pipeline of product candidates includes next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™, NasoShield™ and AdCOVIDTM). For more information on Altimmune, please visit www.altimmune.com.Forward-Looking Statement Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, statements regarding the impact of COVID-19 on our business operations, clinical trials and results of operations, the timing of key milestones for our clinical assets, the development of our AdCOVID vaccine product candidate and initiation of animal testing in Q2 2020 and a Phase 1 clinical study in Q4 2020 for AdCOVID, the filing of the IND for ALT-801 in 2020, the initiation of a Phase 1 clinical study in Q4 2020 and receipt of data from this clinical study in 2021, the initiation of a NasoShield Phase 1b clinical study in June 2020 and receipt of data from this clinical study November 2020, the filing of the IND for HepTcell in 2020, and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
- 05/13/2020
|
Stocks Slide About 2%, Ending NASDAQ's Six-Day Run
- Stocks Slide About 2%, Ending NASDAQ's Six-Day Run
- 05/13/2020
|
Merck’s KEYTRUDA® (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in Head-to-Head Phase 3 Trial
- Merck's KEYTRUDA Superior to Brentuximab Vedotin , a Standard of Care, in Patients with Classical Hodgkin Lymphoma in Head-to-Head Phase 3 Trial
- 05/13/2020
|
Altimmune Appoints Former Pfizer and GSK Executive Diane Jorkasky, M.D. to its Board of Directors
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Diane Jorkasky, M.D. to its Board of Directors. Diane K. Jorkasky, M.D. FACP is a highly regarded pharmaceutical industry executive with a broad background across research and all phases of clinical development in multiple therapeutic areas.
- 05/12/2020
|
Introducing Altimmune (NASDAQ:ALT), The Stock That Collapsed 98%
- Altimmune, Inc. (NASDAQ:ALT) shareholders will doubtless be very grateful to see the share price up 73% in the last...
- 05/09/2020
|
Altimmune to Announce First Quarter 2020 Financial Results on May 14
- GAITHERSBURG, Md., May 08, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the.
- 05/08/2020
|
These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand
- A mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel...
- 05/06/2020
|
Loan dispute puts iProsperity subsidiary in receivership
- The dispute relates to loans provided to iProsperity Underwriting by Alan Caratti's Agricultural Land Trust and funded through its debenture program.
- 05/03/2020
|
$8.8+ Billion Biodefense Industry Insight, 2027: Impact of COVID-19 on the Global Market
- The "Biodefense - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
- 04/24/2020
|
Global Biodefense Market Outlook, 2027: Anthrax Expected to Grow at a Significant Rate Owing to Increased Investments on Production and Stockpiling by Government Agencies - ResearchAndMarkets.com
- The "Biodefense - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
- 04/23/2020
|
Global Biodefense Market is Expected to Reach $8.85 Billion by 2027
- According to Stratistics MRC, the Global Biodefense System market is accounted for $5.47 billion in 2018 and is expected to reach $8.85 billion by 2027 growing at a CAGR of 5.5% during the forecast period.
- 04/21/2020
|
Part of Washington Convention Center to become field hospital for COVID-19 patients
- Parts of the Walter E. Washington Convention Center will be converted into a field hospital.
- 04/20/2020
|
The Race Continues for a COVID-19 Vaccine; 3 Healthcare Stocks to Watch
- The question keeping the world up at night: when will a COVID-19 vaccine be ready? Since China released the virus’ genetic sequence on January 10, researchers in several countries have been working around the clock to develop an effective and safe vaccine. Even though the rapid pace of the development
- 04/13/2020
|
The Race Continues for a COVID-19 Vaccine; 3 Healthcare Stocks to Watch
- The question keeping the world up at night: when will a COVID-19 vaccine be ready? Since China released the virus’ genetic sequence on January 10,
- 04/13/2020
|
D.C., Md., Va. facing budget issues with declines in tax revenue, big coronavirus expenses
- Maryland Gov. Larry Hogan says his state has already spent close to $2 billion on the coronavirus crisis.
- 04/08/2020
|
My Top 4 COVID-19 Tickers For Consideration
- The market is searching for healthcare stocks that could be a major player in the Coronavirus Crisis. My speculative portfolio is loaded with some of these COVI
- 04/06/2020
|
Exclusive: Rockville bio raising $50M, building COVID-19 vaccine — and plotting IPO
- Bill Hearl is CEO and founder of Immunomic Therapeutics in Rockville.
- 04/02/2020
|
COVID-19 Vaccine Updates: J&J Identifies Lead Candidate, IMV Eyes Clinical Testing In Summer, Altimmune Partners With University Of Alabama
- Two coronavirus vaccine candidates are in the clinics and 42 more are in preclinical studies, according to updated data provided by the World Health Organization on March 20.Three biopharma companies issued updates Monday on their developmental efforts for vaccines to combat the deadly virus, which has
- 03/30/2020
|
Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID. In response to the urgent demand posed by the COVID-19 global pandemic, Altimmune has created a COVID-19 vaccine candidate and is currently preparing for immunogenicity studies and manufacture of Phase 1 clinical trial material. Initially, Altimmune will work with UAB investigators on preclinical animal studies and characterization of the vaccine immunogenicity with the goal of enabling a Phase 1 trial in Q3 of this year.
- 03/30/2020
|
‘Breaking into two spheres!’ MoD insider warns coronavirus threatening new Cold War
- CORONAVIRUS could be the start of a new Cold War scenario, as the US and China continue to point the finger at each other, former Ministry of Defence Minister Tobias Ellwood has warned Express.co.uk.
- 03/30/2020
|
Afternoon Market Stats in 5 Minutes
- Movers Indices • S&P 500 ETF (NYSE:SPY) decreased 2.46% to $254.50.• Nasdaq ETF (NASDAQ:QQQ) fell 2.65% to $186.81.• Dow Jones Industrial Average ETF (NYSE:DIA) decreased 3.05% to $217.97.• FTSE/Xinhua China 25 ETF (NYSE:FXI) decreased 5.30% to $36.27.• FTSE Europe ETF (NYSE:VGK) decreased 3.54% to $42.48
- 03/27/2020
|
Fly Intel: Pre-market Movers WW;SCWX;GME;KBH;ALT;OCGN;QFIN;LULU;TXMD;HTZ;GPS
- Fly Intel: Pre-market Movers WW SCWX GME KBH ALT OCGN QFIN LULU TXMD HTZ GPS
- 03/27/2020
|
CCL, RBS among premarket losers
- Arlington Asset Investment (NYSE:AI) -21% after suspending Q1 dividend.BGC Partners (NASDAQ:BGCP) -20% on dividend cut.Altimmune (NASDAQ:ALT) -15% on FY earnings.Arbutus Biopharma (NASDAQ:ABUS) -10% d
- 03/27/2020
|
The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
- Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 26) * Aptevo Therapeutics Inc (NASDAQ: APVO) (reacted to its fourth-quarter
- 03/27/2020
|
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update
- GAITHERSBURG, Md., March 27, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the year ended December.
- 03/27/2020
|
Altimmune Inc to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 27, 2020 / Altimmune Inc (NASDAQ:ALT) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 27, 2020 at 8:30 AM Eastern ...
- 03/27/2020
|
Earnings Scheduled For March 27, 2020
- Companies Reporting Before The Bell
SecureWorks Corp. (NASDAQ: SCWX) is expected to report quarterly loss at $0.01 per share on revenue of $139.13 million.
Sundial Growers Inc...
- 03/27/2020
|
Altimmune to Announce Year End 2019 Financial Results on March 27
- GAITHERSBURG, Md., March 25, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report financial results for the.
- 03/25/2020
|
Largest borrow rate increases among liquid names WLL;BLDP;BHP;TELL;RRC;ALT;HEXO;PLT;LE;INO
- Largest borrow rate increases among liquid names WLL BLDP BHP TELL RRC ALT HEXO PLT LE INO
- 03/12/2020
|
INO, DXC among premarket gainers
- Tiziana Life Sciences PLC (NASDAQ:TLSA) +162% on potential coronavirus treatment.Phio Pharmaceuticals (NASDAQ:PHIO) +24% on Medigene deal.Inovio Pharmaceuticals (NASDAQ:INO) +21%.Altimmune (NASDAQ:ALT
- 03/11/2020
|
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV
- 03/11/2020
|
NVAX, INO among premarket gainers
- Digirad (NASDAQ:DRAD) +63% on Q4 results.Enzo Biochem (NYSE:ENZ) +50% on launch of coronavirus testing service.NanoViricides (NYSEMKT:NNVC) +34% on coronavirus drug progress.TEGNA (NYSE:TGNA) +28% on
- 03/06/2020
|
Healthcare dominates premarket losers amidst coronavirus situation
- Spherix (NASDAQ:SPEX) -25%.Dynatronics (NASDAQ:DYNT) -22%.China Pharma Holdings (NYSEMKT:CPHI) -19%.Co-Diagnostics (NASDAQ:CODX) -17%.Tilray (NASDAQ:TLRY) -14% on Q4 earnings.Cleveland BioLabs (NASDAQ
- 03/03/2020
|
This local bio wants to swiftly deliver a coronavirus vaccine. It will need some help.
- Gaithersburg’s Altimmune is working on a vaccine for the COVID-19 coronavirus.
- 03/02/2020
|
Company News for Mar 2, 2020
- Companies in the news are: ALT, BIG, W, CDXS
- 03/02/2020
|
Stocks To Watch: Time For Coronavirus Offense Or Defense?
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
- 02/29/2020
|
Mid-Afternoon Market Update: Dow Tumbles Over 900 Points; Beyond Meat Shares Plunge On Earnings Miss
- Toward the end of trading Friday, the Dow traded down 3.53% to 24856.01 while the NASDAQ fell 2.29% to 8370.04. The S&P also fell, dropping 2.97% to 2890.26. Coronavirus cases...
- 02/28/2020
|
NVAX, SGMO among premarket gainers
- Dynatronics (NASDAQ:DYNT) +224%.Altimmune (NASDAQ:ALT) +143% on completing first development milestone toward a single-dose intranasal COVID-19 vaccine.Allied Healthcare Products (NASDAQ:AHPI) +103% a
- 02/28/2020
|
Altimmune Completes First Development Milestone Toward a Single-Dose Intranasal COVID-19 Vaccine
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, today announced the advancement of a novel single-dose, intranasal vaccine using Altimmune’s proprietary technology to protect against COVID-19, the disease caused by the SARS-CoV-2 virus. Altimmune has completed the design and synthesis of the vaccine and is now advancing it toward animal testing and manufacturing. “With the spread of COVID-19 outside of China, including the first case of unknown origin in the United States, we have taken action to develop and make our vaccine technology available to help address this crisis,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune.
- 02/28/2020
|
Altimmune to Present at the Cowen 40th Annual Health Care Conference
- GAITHERSBURG, Md., Feb. 19, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Vipin K. Garg, Ph.D., President and Chief.
- 02/19/2020
|
Altimmune to Present at Upcoming Investor and Scientific Conferences
- GAITHERSBURG, Md., Feb. 04, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will present at the following.
- 02/04/2020
|
The Wuhan Coronavirus: 21 Stocks to Watch
- News like the Coronavirus can affect the stock market — either as a whole or just certain stocks and sectors. See how you can prepare.
- 01/29/2020
|
Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer
- Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company today announced that the Company’s immuno-oncology product candidate, ALT-702, met a key pre-clinical efficacy milestone with the demonstration of systemic antitumor activity following intra-tumoral injection in an individual solid tumor. In the study, three doses of ALT-702 were injected into one tumor mass over 5 days with concomitant treatment with an anti-CTLA4 antibody immune checkpoint inhibitor administered intraperitoneally. “These data represent a key milestone for the development of ALT-702 and are highly supportive of the immune-mediated antitumor activity of ALT-702,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune.
- 01/23/2020
|
Altimmune to Present at the 2020 NASH-TAG Conference
- GAITHERSBURG, Md., Jan. 07, 2020 -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an oral presentation at the 2020 NASH-TAG.
- 01/07/2020
|
